Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06097260 · ClinicalTrials.gov registry record · Phase 2
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
A Phase 2 study, sponsored by Pliant Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 320
- Enrollment target
NCT06097260: Clinical Trial Phase 2 study, sponsored by Pliant Therapeutics.
NCT06097260 is a Phase 2 study that was terminated before completion, run by Pliant Therapeutics. The registered enrollment target is 320 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (141% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06097260, a Phase 2 study, was terminated before completion, sponsored by Pliant Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 320 participants
- Enrollment target
Study Summary
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Primary Outcome
The FVC was the total amount of air exhaled from the lungs during the lung function test measured by spirometer. Baseline was defined as data collected prior to and closest to administration of the first dose of study drug (bexotegrast or placebo).
Interventions
- DRUG Placebo
- DRUG PLN-74809
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2023-11-16 |
| Est. Completion | 2025-04-04 |
| Phase | Phase 2 |
Why NCT06097260 stopped before completion
NCT06097260 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (141% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06097260 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06097260 about?
NCT06097260 is a clinical study titled "Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis". A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
What is the current status of trial NCT06097260?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2023-11-16. Estimated completion is 2025-04-04.
What interventions are being tested in trial NCT06097260?
The interventions under investigation include: Placebo (DRUG), PLN-74809 (DRUG).
Who is sponsoring clinical trial NCT06097260?
This trial is sponsored by Pliant Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06097260's enrollment target sits among peer trials
320 152nd of 2000 higher than 1,848 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI